Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388546 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1 | |
| SCHEMBL8765154 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1 | |
| SCHEMBL8766572 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL8765118 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL8765112 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL8765919 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL8765604 | 0.97 | ADRB3 (0.94) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL8765600 | 0.97 | ADRB3 (0.94) | ADRB3ADRB1 | |
| SCHEMBL8765248 | 0.97 | ADRB3 (0.94) | ADRB3ADRB1 | |
| SCHEMBL8765246 | 0.97 | ADRB3 (0.94) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0583485-B1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-13 | — | — | EP | claimed |
| US-5387710-A | Ethanolamine derivatives having sympathomimetic and anti-pollakiuria activities | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-07 | — | — | US | claimed |
| WO-1993015041-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-05 | — | — | WO | claimed |
| US-20090012161-A9 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012161-A9 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | US | disclosed |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | MICHEL MARTIN | 2007-06-07 | — | — | US | disclosed |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | MICHEL MARTIN | 2007-06-07 | — | — | US | disclosed |
| WO-2007036543-A1 | BETA-3-AGONIST USE FOR TREATING KIDNEY AND BLADDER TROUBLES OF A PATIENT WITH SPINAL CORD DAMAGES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-05 | — | — | WO | disclosed |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | MICHEL MARTIN C | 2007-04-05 | — | — | US | disclosed |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | MICHEL MARTIN C | 2007-04-05 | — | — | US | disclosed |
| EP-1769792-A1 | Use of a beta-3 adrenoceptor agonist for the treatment of renal and bladder problems | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| EP-0583485-B1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-13 | — | — | EP | disclosed |
| US-5387710-A | Ethanolamine derivatives having sympathomimetic and anti-pollakiuria activities | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-07 | — | — | US | disclosed |
| WO-1993015041-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885 |
| US-20090012161-A9 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885 |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.